Split (1)

train · 2.59M rows

text stringlengths 9 93k
Rather than emphasizing a return to golf, Tiger's camp stressed to the Golf Channel the focus is on achieving and maintaining a healthy, active lifestyle. One could argue it's merely semantics, yet the subtle change showcases competitive golf -- though far from kaput -- is a distant aspiration for Woods, as he's expect...
A rare opportunity to purchase a unique and architecturally interesting country house, set in just under 2 acres, in a glorious rural setting in north west Herefordshire.
Beautifully situated, and on its own on a quiet country lane, Church House lies on the edge of the small and pretty rural village of Broxwood in north west Herefordshire. Local services are available a short drive away at the larger villages of Weobley, Kington and Pembridge with more extensive facilities available at ...
Built in the mid-1800s, this interesting property comprises an attractive stone house, with mullion windows throughout, and adjoining former Roman Catholic church, which between them create a unique Grade II Listed house which is full of architectural and period features. The accommodation is very versatile and adaptab...
Approached from a small country lane, a private driveway leads to a large parking and large turning area. The front door leads into a welcoming and attractive reception hall with original Victorian tiled floor, mullion windows, and decorative archway. The sitting room has an ornamental stone fireplace and a lovely larg...
From the reception hall, a staircase rises to the first-floor half landing with wc and then to the main landing which provides access to four bedrooms, one of which includes a shower and hand basin, all with their own individual charm and all enjoying a lovely outlook over the gardens to farmland beyond. These rooms ar...
From the driveway access can be gained to a timber car port, which provides covered parking for two cars, with a separate stone outbuilding, which creates a utility area with plumbing and electricity connected. The gardens and grounds are an excellent size and are laid predominately to lawn and enclosed on all sized by...
Services and Considerations mains electricity, mains water, private drainage, oil fired central heating. Central heating throughout. It is not our company policy to test services and domestic appliances, so we cannot verify that they are in working order. Any matters relating to rights of way should be checked with you...
Agents Note: To the far side of the former church, behind beech hedging, is the original small churchyard. There are four war graves from the First and Second World Wars and a number of private graves. These are rarely visited but we understand that two are tended occasionally by family members. There is no public acce...
From Hereford, proceed in a westerly direction on the A465 for approximately 1.5 miles. After passing Wyevale Garden Centre turn right onto the A480 towards Credenhill. Continue on this road for approximately 10 miles to the staggered cross roads at Sarnesfield and proceed straight over towards Lyonshall. After a furth...
A proposal to build a garbage-burning incinerator in Montgomery has been abandoned, the developer who made the proposal has confirmed.
and recycling sorting facility in south Montgomery because of local opposition, both from citizens and the village Board of Trustees.
''I can`t fight City Hall,'' he said.
He made the statement last week following a forum to discuss incineration held by the Environmental Action Coalition, a local environmental group.
unincorporated Boulder Hill began a campaign to prevent the proposal from moving forward.
They formed Montgomery Advocates for Reduction and Recycling, which presented to the board of trustees petitions signed by 582 residents opposing the incinerator.
The full board of trustees will vote Monday on whether to send the letter, but approval is expected.
250 people, including Black Students United Co-Chairs Traciann Celestin '19 and Delmar Fears '19, center, packed into Clark Hall on Tuesday to support BSU after an assault in Collegetown in which a black student said he was punched repeatedly by several white men and called the N-word.
Students, many wearing black in support of BSU, squeezed around tables and sat on the floor of Clark Hall as Delmar Fears ’19 and Traciann Celestin ’19, the co-chairs of BSU, delivered a back-and-forth statement to the U.A.
“Silence is power,” Celestin said.
“Hate speech is not free speech,” Fears continued.
“We will not waste anymore emotional labor than we have already lost explaining basic human rights to this Assembly,” Celestin said.
The refrain, repeated several times over the course of about half an hour, ended with an apparent reference to U.S. Rep. Maxine Waters.
Members of Black Students United and supporters protest at a University Assembly meeting in Clark Hall, Sept. 19, 2017.
Following the statement, Celestin, Fears and hundreds of other students in the room sat and stood silently — some with fists in the air or posters unfurled — as U.A. members, after some procedural quips, sat quietly at the front of the room.
The protest — about four days after a student said he was punched and called the N-word by a group of four or five white men — led the U.A. to task its Codes and Judicial Committee with considering adding a “hate speech” clause to the Code.
Police have arrested a 19-year-old student, John Greenwood ’20, and charged him with misdemeanor assault. Police are still investigating whether to charge the student with a hate crime.
The U.A. charged the CJC with producing a timeline at the next U.A. meeting on Oct. 3 laying out a plan to incorporate an amendment to the Code regarding hate speech by the end of the fall semester, said Gabe Kaufman ’18, chair of the U.A.
The CJC’s task is broad: the committee could satisfy its charge by producing an amendment to the Code that refers to “hate speech” in any way, including simply declaring that it is free speech.
But the CJC could also recommend that the U.A. add a hate speech ban to the Code. Any addition to the Code regarding speech would need the approval of President Martha Pollack, who has pledged to defend free speech.
The CJC effort will be led by Matthew Battaglia ’16, who chairs the committee, which comprises 11 voting members appointed by the U.A. and the four constituent assemblies. A majority is needed to pass an amendment on to the U.A.
“I trust Matt Battaglia … to run an efficient process, an impartial process, a just process, and make sure that any recommendations that come out of the [Codes and Judicial] Committee are fully thought through and are complete,” Kaufman told The Sun.
Kaufman said he thought the committee would “definitely” provide an opportunity, in some fashion, for the public to comment on its ongoing work as it progresses this semester.
Raymond Schlather J.D. ’76, who is representing Greenwood, said in an email that his client “was in no way involved in any physical altercation of any kind” and did not commit a crime.
The proposed changes — regarding maximum suspension length, no-contact orders and more — will need to be approved by President Martha Pollack if they are to go into effect.
When a busy cloud computing platform crashes, the impact is felt widely. That's the case with today's extended outage for Amazon Web Services, which is battling latency issues at one of its northern Virginia data centers. Many high-profile AWS customers are either down or reporting problems.
When a busy cloud computing platform crashes, the impact is felt widely. That's the case with today's extended outage for Amazon Web Services, which is battling latency issues at one of its northern Virginia data centers. The problems are rippling through to customers, causing downtime for many services that use Amazon...
The sites knocked offline by Amazon's problems include social media hub Reddit, the HootSuite link-sharing tool, the popular question-and-answer service Quora, and even a Facebook app for Microsoft (see a full list of affected sites).
The issues began at about 1 a.m. Pacific time and are continuing as of 2:30 p.m. Pacific, with Amazon saying it still cannot predict when services will be fully recovered. By mid-afternoon, Amazon said it had limited the problems to a single availability zone in the Eastern U.S., and was attempting to route around the ...
The problems are focused on Elastic Block Storage (EBS), which provides block level storage volumes for use with Amazon EC2 instances. Latency problems at EBS were cited by Reddit when the site experienced major downtime in March.
"A networking event early this morning triggered a large amount of re-mirroring of EBS volumes in US-EAST-1," Amazon said in a status update just before 9 am Pacific time. "This re-mirroring created a shortage of capacity in one of the US-EAST-1 Availability Zones, which impacted new EBS volume creation as well as the ...
"We are working as quickly as possible to add capacity to that one Availability Zone to speed up the re-mirroring, and working to restore the control plane issue," Amazon continued. "We're starting to see progress on these efforts, but are not there yet. We will continue to provide updates when we have them."
UPDATE: At 10:30 Pacific, Amazon said it was making "significant progress in stabilizing the affected EBS control plane service," which was now seeing lower failure rates. "We have also brought additional capacity online in the affected Availability Zone and stuck EBS volumes (those that were being remirrored) are begi...
UPDATE 2:At 1:48 p.m. Amazon said a single Availability Zone in the US-EAST-1 region continues to experience problems launching EBS backed instances or creating volumes. "All other Availability Zones are operating normally," Amazon said. "Customers with snapshots of their affected volumes can re-launch their volumes an...
The outage even has affected a Microsoft initiative, according to a Facebook post by the company. "For those of you trying to enter our 'Big Box of Awesome' sweepstakes...the entry site is currently down, related to a broader problem impacting a number of sites across the internet today," Microsoft told its Facebook fo...
The outage appears to affect many, but not all, customers using the US-East-1 region. Amazon operates multiple regions, allowing users to add redundancy to their applications by hosting them in several regions. In a multi-region setup, when one region experiences performance problems, customers can shift workloads to a...
Whenever Amazon Web Services experiences outages and performance problems, it typically highlights the multi-region option, which allows customers to avoid having its cloud assets constitute a "single point of failure." Today's outage is likely to prompt some customers that rely on Amazon to examine adding additional r...
The outage is also likely to prompt discussion of the reliability of cloud computing. Is it a fair question to raise? Today's outage has affected many customers, highlighting the vulnerability of a single service hosting many popular sites.
This has also been true of earlier outages at dedicated hosting providers like The Planet or data center hubs like Fisher Plaza. Companies relying upon those facilities could avoid outages by adding backup installations at other data centers - which is essentially the same principle as adding additional zones at Amazon...
Stuff happens. We write about outages all the time. But real-world downtime is particularly problematic in the context of claims that the cloud "never goes down." Cloud infrastructure can also fail. The difference is that cloud deployments offer new options for managing redundancy and routing around failures when they ...
The Federal Reserve should use monetary policy mainly to fight inflation, and "resist the temptation" to use it to achieve financial stability, a top Fed official said on Saturday.
"Financial stability should not be an explicit objective of monetary policy per se," Philadelphia Fed President Charles Plosser said at the American Economic Association's annual meeting.
"Price stability I believe should be the No. 1 priority of a central bank," he said, adding that the Fed's record over its first 100 years on price stability has been less than stellar. Prices have risen by a factor of 30 since the Fed's founding in 1913.
"I think we need to resist the temptation of adding the financial stability goal to the burdens of monetary policy," Plosser said.
Alexion co-founders Steven Squinto and Leonard Bell at their headquarters in Cheshire, Conn. Photo by Evan Kafka for Forbes.
The pharmaceutical business is not kind to entrepreneurs. It takes more than a decade and hundreds of millions of dollars in venture capital to get from cool idea to marketed drug, which is why the founders of Amgen, Genentech and Gilead were gone by the time those companies became big successes.
But nestled near a pastoral local farm 40 minutes outside of New Haven, Conn., amid ears of corn and rows of beets, is the exception to that rule. There, an unassuming, self-deprecating doctor named Leonard Bell still serves as chief executive of Alexion Pharmaceuticals, the company he founded after he quit his medical...
His salvation: Soliris, launched in 2007 to treat a rare cause of anemia. In 2012 that drug will do more than $1.1 billion in revenue, with Wall Street expecting that figure to double again over the next three years. Its current net margin: 22%. Alexion shares are up 600% since the drug's approval--outperforming tech d...
They also point to a paradox in the health care system. Alexion, with 1,100 employees, is a multinational pharmaceutical company with offices in more than 30 countries--but only a few thousand patients the whole world over. Soliris is a blockbuster--and Alexion a juggernaut--because of the drug's astronomical price: $4...
"We focus on patients with absolutely devastating disorders that are also either lethal or life-threatening," says Bell. "They're also very, very rare, so they get no attention from anybody. They're left with no hope, and we only go forward not with treatments that will make it a little bit better but with treatments t...
There is no doubt that Soliris makes a dramatic difference in patients' lives. And unlike most drugs, it seems to help almost every patient who receives it. Take, for instance, Joe Ellenberger, a former college wrestler aspiring to join the Ultimate Fighting Championship, the often brutal mixed martial arts competition...
He won the bout, but his stomach hurt and his urine was black. His fiance convinced him to see a doctor, and after months of tests he was diagnosed with paroxysmal nocturnal hemoglobinuria (PNH), the first disease Soliris was approved to treat. He got the diagnosis over the phone, blithely texted it to his loved ones a...
The results surrounding Soliris' second approved use, for treating a terrible, one-in-a-million kidney ailment called atypical hemolytic uremic syndrome (aHUS), are perhaps more dramatic. Christian Billingsley, now 17, was 3 months old when he started projectile vomiting, the first evidence the disease was attacking ev...
Analysts estimate that the disease could represent many hundreds of millions of dollars a year in sales for Alexion, which underscores the model that the company leverages: There are big profits in solving extremely rare disorders. Soliris is one of at least a dozen drugs whose price for the average patient is greater ...
Treatments for ultrarare disorders tend to sell surprisingly well in nationalized health care systems, especially if they are highly effective. Outside the U.S. Bell sees price pressure on drugs for diseases that afflict tens or hundreds of thousands of people--but not for his drugs.
In the U.S. the Affordable Care Act makes ultraniche drugs "commercially possible by increasing the number of people covered by insurance," says Biotechnology Stock Research's David Miller. "Current and future developers of orphan drugs will strongly benefit from the law."
In fact, the market for these medicines was created by legislation. In 1983 the U.S. enacted a law giving special protection from competition for drugs for rare diseases. In the preceding decade only 10 such drugs were approved. Over the next two decades 282 such medicines followed, according to a 2007 paper in the Int...
That paper warned that the current system may not be sustainable long term. "As the number of orphan drugs increases, and treatments start getting targeted at smaller subpopulations of patients, we can no longer afford to ignore the cost of these treatments," says Duke University's Peter Ubel, one of the study's author...
E. Michael Scott, chairman of the board for the National Organization of Rare Disorders, counters: "I don't think we have a good handle on what it costs to treat some of these patients effectively [without drugs]. The costs of hospital visits, surgery and time in the intensive care unit can be enormous."
Squinto and Bell in 1992, shortly after starting Alexion.
Bell says that the problem of people not having insurance is unique to the U.S., and he chafes at it, a feeling he says goes back to his days as a doctor at Yale (where all people were treated regardless of need) but also to his childhood. He remembers slipping and falling while playing on wet grass at summer camp and ...
"I mean, what kind of 6- or 7-year-old has his insurance with him?" says Bell. "And he literally just put me on the emergency room counter. He was a big guy and he said: 'You have to treat him.' " They did.
Hand to mouth: the hand-written sign Alexion used in its early years.
Alexion was founded in 1992 at the ice cream freezer of a Grand Union grocery store. Bell had gone to fetch sweets for his small children, along with his friend Steve Squinto, an early employee at the biotech Regeneron in Tarrytown, N.Y., who was dating Bell's wife's best friend and had become his buddy. While there Be...
"We had a 1-year-old, a 4-year-old and a 7-year-old, and I was on a tenure-track position at Yale as a physician scientist, and that's when I left Yale," Bell says. He says he can't understand what he was thinking taking such a risk or why his wife let him do it. Bell had caught the entrepreneur bug from his father, wh...
Funding was elusive. After quitting Yale, Bell, every bit the academic, with a mop of dark hair and glasses, went to Prudential Securities with his hand out. That very morning Centocor, one of the hottest biotech stocks of the time, saw its stock implode after a clinical failure. So much for that investment. Worse, wit...
It was saved by the strangest of efforts: At the time, many companies wanted to make pig organs that could be implanted into people. Complement would destroy them, though, so U.S. Surgical gave Alexion $5 million to fund an effort to create pigs with human complement blockers. Then the state of Connecticut ponied up fo...
The goal was to manufacture the antibody against complement that Squinto's researchers had designed, sifting through 10,000 candidates. That antibody would become Soliris, which went into production in 1997. It was tested in rheumatoid arthritis and kidney disease and failed. Alexion's heart drug did no better. The pro...
Alexion's work on paroxysmal nocturnal hemoglobinuria, the disease that would make Soliris a blockbuster, began in the desperate, deep-in-the-red days. Russell Rother, a scientist at Alexion, was assigned to call Peter Hillmen, a hematologist at Leeds Teaching Hospitals in the U.K., to get cells from patients with PNH ...
PNH results almost entirely from the complement system gone awry. Blood cells that lack their complement-blocking armor become the dominant form in the bloodstream, killed by complexes of enzymes aimed at intruders, causing anemia. Red blood cells usually live for four months, but in PNH patients they die in two days. ...
In paroxysmal nocturnal hemoglobinuria, the body destroys its own red blood cells. Credit: Wikipedia.
Hillmen and Rother tried to convince Bell. No dice. Hillmen and Rother remember that the stumbling block was whether such a rare disease could ever be profitable. Hillmen also says there were doubts that he could even deliver enough patients for a clinical trial. Bell says his primary consideration was safety: He was a...
But things changed. Genzyme of Cambridge, Mass. saw its drug Cerezyme, for Gaucher disease, another rare ailment, hit $500 million in annual sales, offering at least the possibility that a rare-disease drug could be successful. And Hillmen had done work showing that patients with severe PNH had few other types of red c...
Every Thursday Rother and Bell sat in a conference room to go over the results from Hillmen's study. Patients required fewer blood transfusions and had less hemoglobin in their blood. But Bell says he was unexpectedly moved by the stories of these 11 patients. One was able to go visit her boyfriend in another country, ...
Bell spent 18 months personally negotiating with the FDA to design the studies that would get Soliris approved. One 87-patient study was placebo-controlled, with only half the patients getting the drug; a second study followed another 97 patients, all of them on Soliris. The drug helped every single one. To prepare the...
Also unique: Their understanding of markets. Analysts had expected Alexion to price the drug at $100,000 to $200,000, but it launched with a much higher price: $390,000.
Cerezyme, the first ultra-orphan drug, paved the way for Soliris (Photo credit: Wikipedia).
Do ultrarare drugs need to be as expensive as Soliris? Hillmen, who played a key role in Soliris' development, says he thinks about that issue often as he gives the drug to patients--though he has never seen the U.K.'s National Health Service decline to give it when it is indicated. "I understand the cost of developing...
Earlier this year, when Vertex Pharmaceuticals received approval for the first drug to treat the lung disease cystic fibrosis, it priced it at $294,000 per patient per year. The medicine works only for a few thousand patients who have a particular genetic mutation. The flood of new discoveries resulting from the plumme...
The biggest problem with Alexion, from an investor's perspective, is that it trades at a shocking 105 times 2011 earnings. In order to justify that multiple, it needs to sustain its astounding pace of growth. Lacking its own pipeline of new drugs, Alexion has been on a buying spree. In December it paid $610 million in ...
But Bell's rarest bet may be Orphatek, a drug bought from a German company a year and a half ago for an undisclosed amount. It treats a disorder in which babies are born missing an enzyme and, as a result, their brains dissolve over the first weeks or months of life. "So it's not life-threatening," says Bell. "It's let...
As best as Bell can tell, there are only ten cases of this disease a year in the U.S., but children given the drug seem to recover remarkably. "So I said, 'Look, if we're doing what we say we're doing and there are babies, we could develop a therapy for where we could change their lives not for 5, 10, 30, 50 but for 70...
Helps to eliminate the fatty clumps that damage the spleen, liver, lungs and bone marrow in Gaucher disease. Cerezyme can cost $300,000 per patient per year.
Treats Hunter syndrome, which causes flattened noses, breathing difficulty and brain damage. Two thousand patients in the world have it. Average cost: $375,000 a year.
Prevents attacks of hereditary angioedema, a dangerous hereditary swelling of the abdomen and lips that can cause suffocation. Average cost: $417,000 a year.
First drug to target a genetic defect at the root of the lung disease cystic fibrosis but only works in patients with a specific mutation. Annual cost: $294,000.
New Gaucher treatment made using genetically modified plant cells. It competes with Cerezyme. Priced at a discount, it still costs hundreds of thousands of dollars a year.
The University of Dayton was named one of the best schools in the nation for students aspiring to launch their own businesses.
The Princeton Review and Entrepreneur magazine listed the University among the Top 25 Undergraduate Schools for Entrepreneurship Studies for the 13th straight year. The program is ranked 19th.
The Princeton Review evaluated hundreds of schools based on the percentage of faculty, students and alumni actively and successfully involved in entrepreneurial endeavors; the number and reach of mentorship programs; funding for scholarships and grants for entrepreneurial studies and projects; the level of support for ...

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.